Effects of disease aetiology on outcomes for unresectable HCC treated with lenvatanib or atezobev: A real world retrospective study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nick Dominelli Whiteley, Jeff Evans, Gregory Naylor
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4406869896
